| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Sunday, June 3, 2018 Nektar Therapeutics’ much-anticipated data from a study pairing its immuno-oncology prospect NKTR-214 with Bristol-Myers Squibb’s checkpoint inhibitor Opdivo seem to have resulted in a lot of head-scratching. |
|
|
| This week's sponsor is ExL Events. | | AI and the Use of Technology to Support Medical Writing - 5th Clinical Regulatory Medical Writing Forum, July 12–13
Learn how AI can streamline content generation in regulatory writing & discuss where medical writing groups can leverage innovative tools to improve the efficiency of their writing capabilities.
Register Today - Save 15% with code C1045FIERCE |
Top Stories Of The Week Thursday, June 7, 2018 Blockbusters such as AbbVie's Humira and Merck's Keytruda will lead 2024 sales, according to an EvaluatePharma report, joined by new Sanofi launch Dupixent. Sunday, June 3, 2018 At this year's ASCO meeting, squamous lung cancer has elbowed nonsquamous disease off center stage—but once again, it's Merck & Co. stealing the spotlight. The drugmaker's PD-1 drug Keytruda showed it could cut the risk of disease worsening or death by 44%, easily topping similar data from Roche's Tecentriq. Wednesday, June 6, 2018 It’s no secret that most ASCO watchers decided Merck's data on immuno-oncology star Keytruda would cement its position as king of the lung cancer market. Its rivals have a thing or two to say, though—chiefly, that differences between their drugs and Keytruda are small to nonexistent. Who's right? Friday, June 8, 2018 News from the 2018 ASCO Annual Meeting, held June 1-5 in Chicago, included some impressive hits and disappointing misses. Check out all of our coverage from the event. Wednesday, June 6, 2018 Pfizer has committed $600 million to its VC fund. The Big Pharma is setting aside 25% of the money for investments in neuroscience startups, giving it a way to continue participating in the field despite its retreat from in-house R&D. Wednesday, June 6, 2018 Personalized CAR-T cells to treat blood cancers can raise the risk of cytokine release syndrome, a frightening collection of symptoms ranging from rash and fever to severe neurological problems. Two new studies suggest that blocking the cytokine IL-1 with a rheumatoid arthritis drug could halt the side effect. Wednesday, June 6, 2018 Medtronic plans to target 4% annual increases in revenue by investing in higher-growth technology markets, transitioning to direct-to-customer deals and further consolidating its global manufacturing footprint. Wednesday, June 6, 2018 Roche’s multiple sclerosis newcomer Ocrevus was approved by the FDA last March bearing a warning about immunization. Now, researchers have gathered clinical data showing it could weaken the effectiveness of certain vaccines. Tuesday, June 5, 2018 The FDA has issued a complete response letter to partners Biocon and Mylan for their version of Sanofi’s blockbuster Lantus insulin, a development they say came as no surprise. Three months ago, the agency noted issues at the manufacturing site where it is produced. Wednesday, June 6, 2018 Gilead Sciences wants people to be upfront about HIV and sex. In new TV awareness ads, actors talk “honestly” about fearing HIV testing or admitting to not using protection. And one of the newer forms of protection is Gilead's Truvada, the only FDA-approved drug to stave off infection. Wednesday, June 6, 2018 SoftBank is considering investing $150 million in the siteless clinical trial company Science 37, which uses telemedicine and real-world data collection to bring studies into participants’ homes, according to reports. | This week's sponsor is ExL Events. | | | |
Enrollment Showcase | | | Sponsored by: Bioinformatics at UTHealth SBMI UTHealth SBMI now offers a M.S. track in clinical and translational bioinformatics. |
|
|
Resources Sponsored by: Blue Latitude Health Blue Latitude Health explores the commercial barriers and new stakeholder connections for pharma companies developing precision medicines, and reveals how to grasp novel opportunities in the new era of healthcare. Presented by: Patheon, part of Thermo Fisher Scientific “Faster and better” has become the mantra for biopharmaceutical companies as they face intense pressure to get therapies to market faster. Quickly proving efficacy in first-in-human (FIH) trials is a make-or-break milestone for these cash-strapped companies whose hopes hinge upon one or two molecules. Read how CDMOs are responding to this pressure. Sponsored by: DocuSign Life science companies are experiencing a significant transformation in how they bring new products to market. |
